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ABSTRACT
Objective: The objective of this selective evidence-based medicine (EBM) review is to
determine whether or not the combined oral contraceptive treatment of 150 mcg levonorgestrel
and 30 mcg ethinyl estradiol is effective in preventing unscheduled uterine bleeding.
Study Design: Review of two randomized controlled trials (RCTs) and one post hoc analysis,
published after 2014 all in the English language.
Data Sources: Two randomized controlled trials (RCTs)
and one post hoc analysis, all of which evaluate the efficacy of the combined oral contraceptive
(COC) treatment of 150 mcg levonorgestrel and 30 mcg ethinyl estradiol in preventing
bothersome unscheduled uterine bleeding. In both RCTs, an experimental group is compared to a
control group receiving an identical appearing placebo. All studies were found using PubMed.
Outcomes Measured: Each of the three articles analyzed the effects of the combined oral
contraceptive of levonorgestrel and ethinyl estradiol in preventing bothersome unscheduled
uterine bleeding. A five-point Likert Scale and bleeding diaries were the methods used to
measure bothersome unscheduled uterine bleeding.
Results: In the studies by Guiahi et al.2 and Hou et al.6, participants receiving the treatment of
combined oral contraceptive showed statistically significant reduction in unscheduled uterine
bleeding compared to the control group with p-values of <0.01 (Guiahi) and 0.03 (Hou). The
study by Nappi et al.7 compared participants with 0-6 and >6 days of bleeding and showed
significant improvement that increased each 91-day cycle of the combined oral contraceptive
treatment with a confidence interval of 95% and an odds ratio (OR) of 1.531.
Conclusions: Based on the systematic review of the two randomized controlled trials and one
post hoc analysis, one can decisively say that 150 mcg levonorgestrel and 30 mcg ethinyl
estradiol is effective in treating bothersome unscheduled uterine bleeding. All three studies
verified statistically significant reduction in bleeding with use of the therapy.
Keywords: Combined oral contraceptive, uterine bleeding, levonorgestrel, ethinyl estradiol, and
unscheduled bleeding.
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INTRODUCTION
Unscheduled uterine bleeding is defined as any bleeding that occurs while using active
contraceptive hormones, excluding bleeding that begins in the hormone-free interval and
continues through days one to four of the subsequent active cycle. 1 A common reason why
women often choose to discontinue hormonal contraception is dissatisfaction with its effects of
uterine bleeding. Interventions that prevent or treat unscheduled bleeding could improve
contraceptive acceptability and increase compliance, thus leading to fewer unplanned
pregnancies.1
In clinical trials, up to 11.3% of women report discontinuation of contraceptives for
bothersome bleeding that is ultimately considered unacceptable. 2 The bleeding pattern most
bothersome to women is unscheduled bleeding or spotting and can occur with all hormonal
methods of contraception.1 Prior to initiation of a contraceptive, healthcare providers should
thoroughly counsel women about the range of bleeding patterns associated with its use.
Providing this education will increase adherence to the method of contraception and reassure
women that if used as directed, unscheduled uterine bleeding does not mean the method is
ineffective at preventing pregnancy.1 However, proper adherence to the method of contraception
does not ensure that bothersome unscheduled uterine bleeding will not continue to occur, causing
women to seek treatment from their healthcare provider.
Seeking a prescribed form of contraceptive requires a minimum of one annual visit for
initiation or maintenance of the contraception. 3 Women should be instructed by their provider to
follow up at any point to discuss side effects or complications. A complication such as
unscheduled bleeding will increase the number of required annual visits for women who seek
treatment.3 There are large differences in cost between different methods of hormonal
contraception, with prescription contraceptives being the most expensive due to requiring
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medical supervision.4 Implants, such as Nexplanon, cost over $800 each.5 Intrauterine devices,
such as the Mirena and ParaGard, cost over $1,000 each. The cost of birth control pills is around
$20 to $50 per pack with monthly purchases adding up to a yearly sum of $240 to $600. The
Depo-Provera shot is $60 each with a total of around $240 per year. NuvaRing totals to
approximately $1,000 per year.5 Since all methods of contraception can result in unscheduled
bleeding, birth control pills are by far one of the most cost-effective options for women seeking
treatment.1,5
The pathogenesis of unscheduled bleeding in women using hormonal contraception is
poorly understood.1 Unscheduled uterine bleeding is thought to be due to a relatively thick
endometrium transitioning to a relatively thin endometrium as a result of the progestin-dominant
component of all hormonal contraceptives.1 Many women find it acceptable to wait for
spontaneous resolution of the problem. For those women who seek an intervention, a
monophasic low-dose combined oral contraceptive (COC) is prescribed. Currently there is no
data supporting one low dose COC over another for this indication. 1,2 However, COCs are
shown to effectively interrupt unscheduled uterine bleeding during treatment. 1,2 This paper
focuses on two randomized controlled trials (RCTs) and one post hoc analysis to evaluate the
efficacy of a combined oral contraceptive treatment to prevent unscheduled uterine bleeding.

OBJECTIVE
The objective of this selective evidence-based medicine review is to determine whether
or not the combined oral contraceptive treatment of 150 mcg levonorgestrel and 30 mcg ethinyl
estradiol is effective in preventing unscheduled uterine bleeding.
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METHODS
The studies used in this systematic review included two randomized controlled trials that
were both double-blind and placebo-controlled, and one post hoc analysis. The population
studied includes women seeking intervention for complaints of bothersome unscheduled uterine
bleeding or bleeding irregularity unrelated to an anatomical or organic source. The intervention
used in each study is a combined oral contraceptive of 150 mcg levonorgestrel and 30 mcg
ethinyl estradiol. Each of the randomized controlled trials utilized an experimental group
receiving an identical appearing placebo as the comparison to the intervention. The post hoc
analysis compared participants who experienced 0-6 days and >6 days of bleeding with each 91day cycle of the treatment. The outcome measured in each study includes the efficacy of the
intervention in providing improvement of unscheduled uterine bleeding.
All studies were discovered in the PubMed database using the key words “combined oral
contraceptive,” “uterine bleeding,” “levonorgestrel and ethinyl estradiol,” and “unscheduled
bleeding.” Each article was published in the English language and in peer-reviewed journals.
Articles were selected based on their relevance to the clinical question and if they included
patient-oriented evidence that matters (POEMS). Inclusion criteria included studies that were
randomized, controlled, and double-blind. Exclusion criteria included studies dated prior to
2007, studies with women under the age of fourteen, and studies with women who were not
experiencing uncontrolled bothersome uterine bleeding. Statistics reported in this review include
number needed to treat (NNT), p-values, control event rate (CER), experimental event rate
(EER), relative risk reduction (RRR), absolute risk reduction (ARR), odds ratio (OR), and
confidence interval (CI). The demographics and characteristics specific to each study can be
found in Table 1.
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Table 1 - Demographics & Characteristics of included studies
Study

Type

Age
(yrs)
1844

Inclusion Criteria

Exclusion Criteria

RCT

#
PTs
32

Guiahi2
(2015)

W/D

Women who were
English or Spanish
speaking with a
bleeding episode of
at least 7
consecutive days at
the time of
enrollment

Hou6
(2016)

RCT

26

1734

Women over the age
of 14 who had
requested
intervention for
complaints of
significant bleeding
irregularity or heavy
flow.

Nappi7
(2017)

Post
hoc
analysis

799

1840

Sexually active adult
women seeking
COC as primary
birth control,
switching from
another COC
regimen, no prior
history of COC use,
women without any
COC use in the last
6 months

Women category
0
3-4 for estrogen
therapy, BMI >35,
BP >135/85
mmHg on more
than 2 occasions,
+pregnancy test,
+chlamydia test,
unable to swallow
pills, severe
medical
conditions, taking
hepatic enzyme
inducing
medications,
allergy to COC,
anatomic source of
bleeding
Women category
2
3-4 for estrogen,
previous treatment
for bleeding with
an etonogestrel
implant,
orthostatic vitals,
organic causes for
the bleeding
Active smokers
112
who were older
than 35.

Interventions
Levonorgestrel
150 mcg and
Ethinyl
Estradiol 30
mcg for 14
days

Levonorgestrel
150 mcg and
Ethinyl
Estradiol 30
mcg for 28
days

Levonorgestrel
150 mcg and
Ethinyl
Estradiol 30
mcg in 91- day
cycles over 1year low dose
ethinyl
estradiol in
replacement of
the normal 7day hormone
free period
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OUTCOMES MEASURED
The outcome measured in each of the studies was the amount of bleeding experienced by
the participants both in the experimental and control groups. Guiahi et al. measured bleeding by
having participants complete a bleeding and pill-taking diary. 2 In the diary, participants recorded
if the pill was taken on the appropriate day, the time the pill was taken each day, and the amount
of bleeding experienced on a scale of none, spotting, light, normal or heavy. 2 Hou et al. reported
changes in bleeding during the last week of the study using a 5-point Likert scale. 6 The scale
included bleeding that improved significantly, improved slightly, no change, worsened slightly,
or worsened significantly.6 Nappi et al. required participants to record bleeding and spotting
episodes daily using electronic diaries with preprogrammed questions. 7 Bleeding was defined as
vaginal blood loss requiring sanitary protection. Spotting was defined as vaginal blood loss that
did not require sanitary protection. Women could only enter information for a given day between
12:00AM and 11:59PM. The electronic diary included an alarm set to the scheduled pill time and
served as a reminder to complete the diary.7
RESULTS
Two randomized controlled trials and one post hoc analysis were used to determine if the
combined oral contraceptive treatment of 150 mcg levonorgestrel and 30 mcg ethinyl estradiol is
effective in preventing unscheduled uterine bleeding. In each of the randomized controlled trials,
the continuous data was able to be converted to dichotomous data. However, in the post hoc
analysis study, the continuous data was not able to be converted.
The randomized controlled trial conducted by Guiahi et al. included 32 women of similar
demographic and reproductive characteristics, all of which reported having bleeding that was
extremely or very annoying.2 See Table 1 for the study’s inclusion and exclusion criteria. The
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women were divided equally into groups either receiving 14 days of the oral contraceptive or an
identically appearing placebo. Throughout the study, each participant completed a daily bleeding
and pill taking diary to ensure compliance to the study. Only one participant in the oral
contraceptive arm was noncompliant with protocol by missing a pill on days 11 and 12 and
taking two pills on days 13 and 14.2 Intent to treat analysis was performed and there was no loss
to follow-up in the study. No adverse events were reported by any of the participants during the
study. The primary outcome measured on completion of the study was temporary interruption of
bleeding during therapy. Out of the participants in the experimental group receiving 14 days of a
combined oral contraceptive containing 150 mcg levonorgestrel and 30 mcg ethinyl estradiol, 14
out of 16 participants (87.5%) admitted to interruption of bleeding compared to 6 out of 16
participants ( 37.5%) receiving an identical placebo.2 The study determined that participants
receiving the oral contraceptive were 11.7 times more likely than the placebo group to have
temporary interruption of bleeding.2 The study was determined to be statistically significant with
a p-value <0.01 and a confidence interval (CI) of 95%. The results calculated from this
randomized controlled trial are summarized in Table 2.
Table 2- Efficacy of the COC in preventing unscheduled uterine bleeding, Guiahi et al. 2
CER

EER

RRR

ARR

NNT

0.375

0.875

1.33

0.5

2.0

Confidence Interval (CI)= 95%

p-value= <0.01

Hou et al. conducted a double-blind, placebo-controlled, randomized controlled trial on
26 women reporting troublesome bleeding.6 The women were divided into an experimental
group receiving a combined oral contraceptive of 150 mcg levonorgestrel and 30 mcg ethinyl
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estradiol or an identical placebo for twenty-eight days. See Table 1 for the study’s inclusion and
exclusion criteria. On days 22-28 of the study, the participants were asked to attend a follow up
visit to inform the study staff if the treatment had improved bleeding using a 5-point Likert scale.
In both the experimental and control groups, 12 out of 13 women returned for follow up. In the
group receiving the combined oral contraceptive, 11 (92%) noted significant improvement in
bleeding compared to 5 (42%) receiving the placebo. 6 The study was determined to be
statistically significant with a p-value of 0.03. Losses to follow-up for the study was determined
to be <20% since 24 out of 26 participants completed the study. The results calculated from this
randomized controlled trial are summarized in Table 3. Adverse events reported in the study
included headache (n=10), nausea or vomiting (n=3), cramping (n=3), and breast tenderness
(n=4).6
Table 3- Efficacy of the COC in preventing unscheduled uterine bleeding, Hou et al. 6
CER

EER

RRR

ARR

NNT

0.42

0.92

1.19

0.5

2.0

p-value= 0.03

The post hoc analysis of a multicenter, open-label, 1-year, Phase 3 study conducted by
Nappi et al. evaluated scheduled and unscheduled bleeding and spotting with the thought that
ovarian suppression may result in improved cycle control and reduced risk of unscheduled
bleeding.7 The study was conducted over one year with all participants receiving the treatment of
a 91-day extended regimen of the combined oral contraception 150 mcg levonorgestrel and 30
mcg ethinyl estradiol for 84 days, and ethinyl estradiol 10 mcg in place of the traditional 7-day
hormone-free interval.7 The study observed 799 women who completed at least one 91-day cycle
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of therapy and reported their bleeding and spotting episodes using daily electronic diaries. 7 See
Table 1 for the study’s inclusion and exclusion criteria. Table 4 summarizes the percentage of
women for each cycle completed that reported unscheduled bleeding lasting less than six days or
greater than six days. There was a 53% increase in the likelihood of women reporting 0-6 days
versus greater than 6 days of unscheduled bleeding during days 1-84 for each additional 91-day
cycle. The results led to an odds ratio (OR) of 1.531 and a confidence interval (CI) of 95%
shown in Table 5.7 It was reported that there were more than one in five women reporting no
bleeding by the third and fourth cycles of the study. Examination of study discontinuation
showed 10% (80/799) discontinued due to an adverse event with 4% (32/799) due to bleeding
and spotting adverse effects. The safety of this extended regimen combined oral contraceptive
treatment is supported in that there was no accumulation of hormones, no unexpected changes to
the endometrium, no effect of cycle length on hemostatic biomarkers, and similar incidence rates
of adverse events over four years of continuous use compared with the conventional 28-day
cycle.
Table 4- Percent of women reporting unscheduled bleeding, Nappi et al. 7
Days of bleeding
0-6 Days

Cycle 1
n=758
65%

Cycle 2
n=625
81%

Cycle 3
n=533
85%

Cycle 4
n=446
85%

>6 Days

35%

19%

15%

15%

*n= number of participants for each cycle
Table 5- Efficacy of the COC in preventing unscheduled uterine bleeding, Nappi et al. 7
Odds Ratio (OR)

Confidence Interval (CI)

1.531

95%
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DISCUSSION
The two randomized controlled trials and post hoc analysis discussed in this systematic
review determined the efficacy of a combined oral contraceptive’s ability to treat bothersome
unscheduled uterine bleeding. All three studies showed significant improvement of unscheduled
bleeding with either minimal or no adverse events. Each study demonstrated statistically
significant outcomes with p-values of <0.01, 0.03, or confidence intervals of 95%. 2,6,7
It is important to note that the studies done by Guiahi et al. and Hou et al. included
participants that along with receiving the combined oral contraceptive during the study, also had
an etonogestrel contraceptive implant with which they were experiencing bothersome uterine
bleeding.2,6 Participants in the study conducted by Nappi et al. did not have an etonogestrel
implant during the study.7
The combined oral contraceptive levonorgestrel and ethinyl estradiol is primarily used for
the prevention of pregnancy.8 Some off-label uses include abnormal uterine bleeding,
dysmenorrhea, hirsutism, menorrhagia, pain associated with endometriosis, and polycystic ovary
syndrome (PCOS).8 Contraindications to usage include breast cancer or other estrogen or
progestin dependent neoplasms, hepatic tumor or disease, pregnancy, and Hepatitis C drug
combinations containing ombitasvir/paritaprevir/ritonavir, with or without dasabuvir. 8 It is also
contraindicated in women at high risk of arterial or venous thrombotic diseases. The US boxed
warnings for levonorgestrel and ethinyl estradiol include cigarette smoke and cardiovascular
events.8
There were several limitations to the studies used in this review. The study conducted by
Guiahi et al. had a limited protocol in which the first day of bleeding after therapy was the end of
that individual’s participation in the study.2 This prevented the study from reporting on the long-
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term bleeding patterns after a single 14-day treatment. A larger study would be needed to
confirm the results of the sample and to determine if any patient characteristics influence
success. Due to the small sample size in the study by Hou et al., the study population was too
small for substantial subgroup and regression analyses. 6 Since the study only included women
seeking treatment for their bleeding, it did not represent all women who have a bleeding issue
with the etonogestrel implant, but instead those who have more extreme bleeding complaints
creating another limitation to this study. Limitations to the study by Nappi et al. include its openlabel design and lack of a comparison group for evaluation of change in bleeding over time. 7 The
study also lacked correction to unscheduled bleeding/spotting when missed pill episodes were
reported.
CONCLUSIONS
Based on the current research available, it can be determined that yes, the combined oral
contraceptive of 150 mcg levonorgestrel and 30 mcg ethinyl estradiol is effective in treating
bothersome, unscheduled uterine bleeding. All three studies in this review demonstrated
statistically significant data that supported improvement in bleeding for participants receiving the
combined oral contraceptive treatment. 2,6,7 A flaw in the methods used by these studies that
could be corrected in future studies is finding a less subjective way to monitor the amount of
bleeding experienced by the participants. For example, bleeding that is considered heavy to one
participant may be normal to another. Future study is warranted to further evaluate the long-term
acceptability of bleeding, and length of the treatment’s effect, after use of combined oral
contraceptives to treat bothersome bleeding episodes.
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